Testicular Cancer
Aetiology
- Most common solid cancer in men 20-45
- Seminomatous - 35-45 years
- Non-seminomatous (teratoma) - < 35 years
Risk factors
- Previous TC - increased risk in contralateral testicle
Pathophysiology
- Germ cell tumours, 2 main types:
Seminoma
- Arise from seminiferous tubules
- Cure rate 95%, extremely responsive to radiotherapy even if relatively advanced
Teratoma
- Often far more aggressive and can metastasize
- Very chemosensitive even with metastasis
- Rarely exist as 'pure' tumours; usually associated with other non-seminomatous cell types (e.g. yolk sac, embryonal, choriocarcinoma)
- Prognosis dependent on sub-types present and the relative proportion
Other types
- Yolk sac tumour - can produce alpha feto protein
- Embryonal cell carcinoma - aggressive form, looks high grade and is associated with frequent metastasis
- Choriocarcinoma - positive for beta HCG, positive pregnancy test
Clinical presentation
Symptoms
- Delayed presentation occasionally seen
- Acute pain due to bleeding
- Symptoms of advanced disease: weight loss, neck lumps, chest symptoms or bone pain
Signs
- Asymmetry or slight scrotal discolouration
- Hard, non-tender, irregular mass mostly intratesticular
- Assess involvement of epididymis, spermatic cord and scrotal skin
- Abdominal mass, lymphadenopathy - advanced disease
Investigations
- Imaging - US testicle, CT chest abdomen for staging
- Bloods:
- Tumour markers
- Alpha-fetoprotein may be raised in teratomas (not seminomas)
- Beta-hCG may be raised in teratomas and seminomas, but more often in teratomas
- Lactate dehydrogenase
- FBC
- LFTs
- Renal function tests
Management
- Generally a good prognosis even at an advanced stage
- Radical inguinal orchidectomy
- Re-check tumor markers 1 week post-op if they are elevated pre-op
- Further followup by oncologist
- Chemotherapy as adjuvant treatment even in non-metastatic cases
Made with Bullet